Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -25.13% is 56% above its 3-year average of -57.10%, near the high end of its 3-year range (-140.43%–21.71%).
344.39% below its 12-month average of -5.66%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.41%.
RETURN ON ASSETS (ROA)
-25.13%
RETURN ON ASSETS (ROA) AVG TTM
-5.66%
RETURN ON ASSETS (ROA) AVG 3Y
-57.10%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-344.39%
CURRENT VS 3Y AVG
+55.99%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.81%
median of 819 covered companies
CURRENT VS SECTOR MEDIAN
+21.00%
vs the sector median at left
Maze Therapeutics, Inc.
Market Cap
$1.43B
Return on Assets (ROA)
-25.13%
TTM Avg
-5.66%
3Y Avg
-57.10%
5Y Avg
N/A
Market Cap
$1.43B
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Return on Assets (ROA)
-46.39%
TTM Avg
-37.70%
3Y Avg
-40.46%
5Y Avg
-33.71%
Market Cap
$1.44B
Return on Assets (ROA)
-4.89%
TTM Avg
-0.43%
3Y Avg
-0.87%
5Y Avg
-1.37%
Market Cap
$1.41B
Return on Assets (ROA)
61.75%
TTM Avg
-16.82%
3Y Avg
-22.73%
5Y Avg
-17.45%
Market Cap
$1.41B
Return on Assets (ROA)
3.12%
TTM Avg
3.19%
3Y Avg
2.54%
5Y Avg
2.30%
Market Cap
$1.45B
Return on Assets (ROA)
14.98%
TTM Avg
6.07%
3Y Avg
5.42%
5Y Avg
6.72%
Market Cap
$1.46B
Return on Assets (ROA)
-16.72%
TTM Avg
-18.71%
3Y Avg
-15.50%
5Y Avg
-12.14%
Market Cap
$1.46B
Return on Assets (ROA)
-29.88%
TTM Avg
-23.31%
3Y Avg
-25.68%
5Y Avg
-25.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.43B | -25.13% | -5.66% | -57.10% | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | -46.39% | -37.70% | -40.46% | -33.71% |
| Certara, Inc. (CERT)vs › | $1.44B | -4.89% | -0.43% | -0.87% | -1.37% |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 61.75% | -16.82% | -22.73% | -17.45% |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 3.12% | 3.19% | 2.54% | 2.30% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 14.98% | 6.07% | 5.42% | 6.72% |
| GH Research PLC (GHRS)vs › | $1.46B | -16.72% | -18.71% | -15.50% | -12.14% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.46B | -29.88% | -23.31% | -25.68% | -25.68% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | -21.52% | -21.52% | -21.52% | -21.52% |
ROA
-25.1%
ROE
-29.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -33.02% |
| 2024-12-31 | 21.71% |
| 2023-12-31 | -140.43% |
| 2022-12-31 | -76.65% |
